NOUVELLE PHARMACIE DES GARRIGUES : revenue, balance sheet and financial ratios

NOUVELLE PHARMACIE DES GARRIGUES is a French company founded 14 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in MARGUERITTES (30320), this company of category PME shows in 2021 a revenue of 2.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - NOUVELLE PHARMACIE DES GARRIGUES (SIREN 533727848)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue N/C N/C N/C N/C 2 441 577 € 2 381 091 € 2 274 233 € 2 234 312 € 2 054 741 € 2 070 814 €
Net income 141 626 € 161 722 € 187 152 € 141 561 € 134 087 € 136 943 € 138 024 € 121 140 € 73 823 € 53 254 €
EBITDA N/C N/C N/C N/C 186 357 € 195 250 € 186 269 € 197 043 € 114 256 € 140 772 €
Net margin N/C N/C N/C N/C 5.5% 5.8% 6.1% 5.4% 3.6% 2.6%

Revenue and income statement

In 2025, NOUVELLE PHARMACIE DES GARRIGUES generates positive net income of 142 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 53 k€ -> 142 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

141 626 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 49%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

49.127%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

57.631%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

18.3%

Solvency indicators evolution
NOUVELLE PHARMACIE DES GARRIGUES

Sector positioning

Debt ratio
49.13 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good +14 pts over 3 years

In 2025, the debt ratio of NOUVELLE PHARMACIE DES GA... (49.13) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
57.63% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good

In 2025, the financial autonomy of NOUVELLE PHARMACIE DES GA... (57.6%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 113.28. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

113.275

Liquidity indicators evolution
NOUVELLE PHARMACIE DES GARRIGUES

Sector positioning

Liquidity ratio
113.28 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch +9 pts over 3 years

In 2025, the liquidity ratio of NOUVELLE PHARMACIE DES GA... (113.28) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
NOUVELLE PHARMACIE DES GARRIGUES

Positioning of NOUVELLE PHARMACIE DES GARRIGUES in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of NOUVELLE PHARMACIE DES GARRIGUES is estimated at 2 249 745 € (range 1 526 688€ - 3 530 161€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
1526k€ 2249k€ 3530k€
2 249 745 € Range: 1 526 688€ - 3 530 161€
NAF 5 année 2025

Valuation method used

Net Income Multiple
141 626 € × 15.9x = 2 249 746 €
Range: 1 526 688€ - 3 530 161€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare NOUVELLE PHARMACIE DES GARRIGUES with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about NOUVELLE PHARMACIE DES GARRIGUES

What is the revenue of NOUVELLE PHARMACIE DES GARRIGUES ?

The revenue of NOUVELLE PHARMACIE DES GARRIGUES in 2021 is 2.4 M€.

Is NOUVELLE PHARMACIE DES GARRIGUES profitable?

Yes, NOUVELLE PHARMACIE DES GARRIGUES generated a net profit of 142 k€ in 2025.

Where is the headquarters of NOUVELLE PHARMACIE DES GARRIGUES ?

The headquarters of NOUVELLE PHARMACIE DES GARRIGUES is located in MARGUERITTES (30320), in the department Gard.

Where to find the tax return of NOUVELLE PHARMACIE DES GARRIGUES ?

The tax return of NOUVELLE PHARMACIE DES GARRIGUES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does NOUVELLE PHARMACIE DES GARRIGUES operate?

NOUVELLE PHARMACIE DES GARRIGUES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.